3D Printed Silicone Coronary Artery Simulator for Percutaneous Coronary Interventional Training
Launched by CHINA NATIONAL CENTER FOR CARDIOVASCULAR DISEASES · Jun 4, 2020
Trial Information
Current as of June 25, 2025
Unknown status
Keywords
ClinConnect Summary
With the aging of the population, the incidence of cardiovascular diseases has exceeded that of respiratory diseases and cancer, corresponding to the rapid increase in the number of coronary stent implantation. Therefore, the standardized training of interventional cardiologists is particularly important. Nowadays percutaneous coronary intervention (PCI) training mode is mainly for the trainees to operate on the patients under the experienced operator. Although this kind of training method can truly show the operation process, it has obvious limitations. For beginners, it takes repeated tra...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Previous experience in coronary intervention
- • Understand the process of trail and be willing to participate
- Exclusion Criteria:
- • No previous experience with coronary intervention
- • Unwilling to participate the trail
- • Unable to complete the trail due to other problems
About China National Center For Cardiovascular Diseases
The China National Center for Cardiovascular Diseases (NCCD) is a leading research and clinical trial sponsor dedicated to advancing cardiovascular health in China and globally. As a prominent institution, NCCD focuses on innovative research, clinical management, and education in cardiovascular medicine. The center plays a crucial role in conducting rigorous clinical trials aimed at developing new therapies and improving patient outcomes for cardiovascular diseases. Through collaboration with national and international partners, NCCD is committed to enhancing the understanding of cardiovascular conditions and translating research findings into practical applications for improved healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Patients applied
Trial Officials
Shubin Qiao, MD,PhD
Principal Investigator
Fuwai Hospital, Beijing, China
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials